Merck details PhII TIGIT/PD-1 fail in lung cancer

Nine months after revealing that its TIGIT/PD-1 combo failed a mid-stage lung cancer study, Merck is spelling out the full results — with the combo missing all the primary and secondary endpoints.

Despite the flop, Merck kept going with a slate of Phase III studies it had already launched for…
Click here to view original post

Advertisement — Advertise with Biotech Networks